Drug Type Small molecule drug |
Synonyms GSK 372475, GSK-372475, NS 2359 |
Target |
Action- |
Mechanism Dopamine reuptake inhibitors, Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H19Cl2NO |
InChIKeyFPTPUYCHSWIWIB-FUTJPDQTSA-N |
CAS Registry195875-87-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cocaine-Related Disorders | Phase 2 | United States | 01 May 2016 | |
Depressive Disorder, Major | Phase 2 | Bulgaria | 19 Dec 2006 | |
Depressive Disorder, Major | Phase 2 | Canada | 19 Dec 2006 | |
Depressive Disorder, Major | Phase 2 | Chile | 19 Dec 2006 | |
Depressive Disorder, Major | Phase 2 | Costa Rica | 19 Dec 2006 | |
Depressive Disorder, Major | Phase 2 | Croatia | 19 Dec 2006 | |
Depressive Disorder, Major | Phase 2 | France | 19 Dec 2006 | |
Depressive Disorder, Major | Phase 2 | Germany | 19 Dec 2006 | |
Depressive Disorder, Major | Phase 2 | India | 19 Dec 2006 | |
Depressive Disorder, Major | Phase 2 | Italy | 19 Dec 2006 |
Phase 2 | 55 | (NS2359) | hncbkneozo = ejaujrzqji voeriodvol (isjknxqypw, simgmjtnfs - fizeqbgooe) View more | - | 24 May 2021 | ||
placebo (Placebo) | hncbkneozo = cihvrvqezw voeriodvol (isjknxqypw, anrfywfeua - cffrkexwzq) View more | ||||||
Phase 2 | 492 | Placebo | henreqpkrs(yddufcepbs) = nevjbmatbk lrdwwappkh (lruuhwubcg, 9.97) View more | - | 05 Feb 2018 |